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Background: During the pre-reperfusion era, plasma glucose on admission for ST-elevation myocardial infarction (STEMI) was considered a marker of 
the severity of myocardial damage, however data is lacking on the relationship between plasma glucose on admission and outcomes of patients with 
STEMI treated with primary percutaneous coronary intervention (PCI). We evaluated the impact of admission blood glucose in patients without a history of 
diabetes on clinical outcomes in the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
Methods: The HORIZONS-AMI trial included 3602 patients with STEMI undergoing primary PCI. There were 3006 patients without history of 
diabetes and admission blood glucose was available for 2839 patients .
Results: The main outcomes are presented in the Table. Higher plasma glucose on admission was associated with higher rates of ischemic 
events and major bleeding at 30-days and 1-year. By multivariable analysis, higher plasma glucose value was predictive of higher rates of 30-day 
reinfarction (1st vs 3rd tertile HR [95% CI] = 0.26 [0.11, 0.61], p=0.049), ischemic target vessel revascularization (TVR) 1st vs. 3rd (1st vs 3rd 
tertile HR [95% CI] = 0.33 [0.16, 0.69], p=0.003) and MACE (1st vs 3rd tertile HR [95% CI] = 0.33 [0.19, 0.59], p=0.0002) 
Events, %
Patients with STEMI and plasma glucose on admission (tertiles)
p≤ 118.8 mg/dL
n=942
>118.8 to ≤ 145 mg/dL
n=933
>145 mg/dL
n=964
At 30 days
Death 0.5% 0.9% 4.8% <0.0001
Reinfarction 0.7% 1.6% 2.8% 0.003
Ischemic TVR 1.1% 2.6% 2.8% 0.018
Stroke 0.4% 0.6% 0.9% 0.4
Definite/probable stent thrombosis (ARC)± 1.0% 2.5% 3.3% 0.005
Major Bleeding (non-CABG related) 3.4% 8.3% 8.8% <0.0001
TIMI Major Bleeding 1.6% 3.8% 6.8% <0.0001
GUSTO severe/life threatening/moderate bleeding 1.7% 3.9% 7.6% <0.0001
MACE* 2.2% 3.8% 8.7% <0.0001
Net adverse clinical events† 5.5% 10.5% 15.2% <0.0001
At 1 year
Death 1.5% 2.3% 7.1% <0.0001
Reinfarction 3.7% 3.7% 4.5% 0.49
Ischemic TVR 6.3% 5.9% 6.6% 0.85
Stroke 0.8% 1.0% 1.1% 0.76
Definite/probable stent thrombosis (ARC) 2.9% 3.6% 3.6% 0.58
Major Bleeding (non-CABG related) 4.0% 8.7% 9.5% <0.0001
TIMI Major Bleeding 1.8% 4.0% 7.3% <0.0001
GUSTO severe/life threatening/moderate 2.3% 4.1% 8.1% <0.0001
MACE 9.7% 9.3% 14.8% <0.0001
Net adverse clinical events† 12.8% 15.9% 20.2% <0.0001
*Death, reinfarction, ischemic target vessel revascularization (TVR) or stroke
†MACE or protocol defined non-CABG major bleeding
± Academic Research Consortium
Conclusion: Admission plasma glucose in the absence of history of diabetes is an important marker of ischemic and bleeding complications in 
patients with STEMI treated with primary PCI.
